

NEWS RELEASE

Pharmaniaga Poised for Growth

PETALING JAYA, March 31, 2015 – As a leader in the pharmaceutical sector, both in Malaysia and regionally, Pharmaniaga Berhad is set to strengthen its position as it maintains its growth momentum.

The Group delivered an exceptional performance in the financial year ended 31 December 2014, spurred by favourable growth in the global pharmaceutical industry. The Group registered a profit before tax of RM126 million, a significant 35% jump from RM93 million in the last financial year and the highest in Pharmaniaga's 17-year history. Revenue grew to RM2.1 billion for the year under review, a 9% increase compared with the previous year. This was achieved on the back of increased demand from both concession and private businesses.

In tandem with the Group's commendable performance, Pharmaniaga declared a net dividend per share of 28 sen for the financial year ending 31 December 2014, compared with 16 sen in the previous year.

YBhg Tan Sri Dato' Seri Lodin Wok Kamaruddin, Chairman, Pharmaniaga Berhad, commented after Pharmaniaga's Annual General Meeting, "Pharmaniaga's firm position in the pharmaceutical sector enabled us to capitalise on positive market conditions in 2014 to deliver a sterling performance. In line with our commitment to delivering shareholder value, we are glad to reward our shareholders with a significant 77% dividend payout ratio, which reflects a 6.1% yield based on the closing price for the year."

“During the year under review, we continued to expand our presence in the growing healthcare and pharmaceutical industries in Malaysia and other emerging markets. Moving forward, we will maintain our focus on tapping into new opportunities for growth in order to enhance our core businesses. To this end, Pharmaniaga recently entered into supply agreements with Universiti Malaya, Universiti Kebangsaan Malaysia and Universiti Sains Malaysia.”

The agreements will see Pharmaniaga providing products and services to the respective university hospitals. This will include purchasing, storing, supplying and delivering pharmaceutical products. The contract period extends to November 2019.

“We are confident that by leveraging on the inherent prospects of the industry, we will be able to enhance our market reach and strengthen our earnings potential in the long run as we strive to move up the value chain,” concluded YBhg Tan Sri Dato’ Seri Lodin.

Forward looking statements

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

-ends-

Issued on behalf of: Pharmaniaga Berhad By: acorn communications sdn bhd For further information, please contact Lilyza Joehai at 019 664 3838 or Yasmin Kadir at 017 237 9048 Or 03 7958 8348 or email acorncommunications@acornco.com.my
